Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Visabl.com, a cloud-based antibody and biomarker search engine, announced its largest website update. The latest iteration of the Visabl website features several enhancements and improvements to the site and user interface, including a faster targeted search of biomarkers and the ability to dynamically sort and populate results as the user types.
Sekisui Diagnostics launched the Sekure brand of clinical chemistry reagents. Sekisui develops, manufactures, and supplies clinical chemistry reagents and systems to the in vitro diagnostics industry, selling more than 1.5 billion clinical chemistry tests per year.
EDP Biotech has entered into distribution agreements with more than 25 distribution channel partners throughout Europe, Asia, and South America. EDP plans a multiphase rollout of ColoMarker, a blood test that aids in the detection of early stage colorectal cancer, in 2015 to gain experience and data in conjunction with key opinion leaders and distributor partners.
Copan has obtained FDA clearance for its FecalSwab, which comprises a regular size Copan flocked swab (FloqSwab) and a screw-cap tube containing 2 mL of Cary-Blair medium. FecalSwab is intended for the collection of rectal swabs and fecal specimens and to preserve the viability of enteric pathogenic bacteria during transport from the collection site to the testing laboratory.
Bruker has announced what it says is a major expansion of its Mycobacteria Library for research use only on the MALDI Biotyper microbial mass spectrometry system.
The Institute for Life Science Entrepreneurship and ATCC will collaborate to establish the ATCC Center for Translational Microbiology at ILSE. The focus of the center will be on key challenges identified by both ATCC and ILSE in current translational microbiology, including antimicrobial resistance, synthetic biology, microbial bioinformatics, and the microbiome.
Microbiologics has launched a Business Solutions division dedicated to partnering with diagnostic and life science technology manufacturers. Users of these instruments and assays need biological controls to meet regulatory requirements for validation, verification, and quality control.
InSphero released its GravityTrap Ultra-low Attachment (ULA) Plate. The automation-compatible 96-well ULA format is well suited for production of 3-D tumor microtissues derived from tumor cell lines or to screen for the propensity of cells to form spheroids in a low-attachment environment.
Great Basin Scientific announced the FDA clearance and commercial availability of its molecular diagnostic test for group B streptococcus. The group B strep assay provides accurate results in approximately 90 minutes with a specimen from enriched LIM broth. By targeting a highly conserved region of the cfb (CAMP factor) gene, the molecular assay provides definitive identification and a more rapid diagnosis of the mother’s GBS colonization status compared to standard culture-based tests, which may take up to an additional 48 hours.
Horizon Discovery Group and Transgenomic announced a new original equipment manufacturer agreement to incorporate Horizon’s human genomic reference standards, produced by Horizon’s diagnostics division, into Transgenomic’s Multiplexed ICE COLD-PCR (MX-ICP) kits for use in research and clinical applications. Further details of the agreement were not disclosed.
